Intraventricular administration of a FIV-envelope protein induces sleep architecture changes in rats.
Fifteen adult male Sprague-Dawley rats were implanted with a set of electrodes for standard sleep recordings. A stainless steel cannula was also implanted into the lateral ventricle of these rats. Fifteen additional rats were implanted with a cannula alone. Rats with electrodes were habituated for 3 days or more to the recording environment, then placed into 3 groups (n = 5). One group received saline (i.c.v.), while the other two groups received either the feline immunodeficiency virus envelope glycoprotein (FIV SU-Env) or a fragment of the Epstein-Barr virus envelope glycoprotein (EB gp105). Rats were then recorded for electrographic sleep-wake cycle evaluation for the following 4 h. Core temperature was assessed through a thermistor probe inserted into the rectum, immediately before and 1, 2, 3 and 4 h after the i.c.v. treatment condition. Results demonstrated that compared to saline, FIV SU-Env increased wakefulness and decreased REM sleep throughout the 4 h of recording. Likewise, FIV SU-Env decreased SWS2 for 2 h. In addition, EB gp105 administration elicited minor modifications of the sleep-wake cycle, causing only a transient reduction of REM sleep in the first hour of recording. None of the treatments altered body temperature. These findings strongly support and extend studies in FIV-infected cats in which we have found similar sleep abnormalities. In addition, these results are consistent with the hypothesis that the FIV SU-Env proteins are responsible for these neurological disturbances.(ABSTRACT TRUNCATED AT 250 WORDS)
Prospéro-García
O
O
Department of Neuropharmacology CVN-13, Scripps Research Institute, La Jolla, CA 92037.
Herold
N
N
Waters
A K
AK
Phillips
T R
TR
Elder
J H
JH
Henriksen
S J
SJ
D000818:Animals; D001921:Brain / Q000502:physiology*; D004569:Electroencephalography; D015683:Gene Products, gag / Q000008:administration & dosage* / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012894:Sleep Stages / Q000187:drug effects*; D014759:Viral Envelope Proteins / Q000008:administration & dosage* / Q000494:pharmacology; D014851:Wakefulness / Q000187:drug effects
D015683:Gene Products, gag; D010446:Peptide Fragments; D014759:Viral Envelope Proteins; C074662:p24 protein, Feline immunodeficiency virus